All In Biotech

Drug Trial Radar · NCT06632600

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

A Randomized, Participant- and Investigator-blinded, Controlled, Parallel Group Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LXE408 in Participants With Chronic Chagas Disease Without Severe Organ Dysfunction.

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Apr 28, 2025

Primary completion

Jul 22, 2027

Study completion Jan 21, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.

Conditions

  • Chagas Disease

Interventions

  • LXE408Drug

    LXE408 administered by oral route

  • PlaceboDrug

    Placebo administered by oral route

  • BenznidazoleDrug

    Benznidazole administered by oral route (administered as standard of care)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence or absence of sustained parasitological clearance using polymerase chain reaction (PCR) results over 6 months - LXE408 28 days versus placebo.Time frame: At Months 2, 4, and 6

Locations

22 sites in 4 countries. Site status is shown where the registry gives one.

  • Olive View UCLA Educ and Res Ins

    Sylmar, California · Recruiting

  • University of Florida Shands

    Gainesville, Florida · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • Novartis Investigative Site

    Caba, Argentina · Recruiting

  • Novartis Investigative Site

    Corrientes, Argentina · Recruiting

  • Novartis Investigative Site

    Formosa, Argentina · Recruiting

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina · Recruiting

  • Novartis Investigative Site

    Córdoba, Córdoba Province, Argentina · Recruiting

  • Novartis Investigative Site

    Montes Claros, Minas Gerais, Brazil · Recruiting

  • Novartis Investigative Site

    Recife, Pernambuco, Brazil · Recruiting

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Novartis Investigative Site

    São Caetano do Sul, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Bogotá, Colombia · Recruiting

  • Novartis Investigative Site

    Bogotá, Colombia · Recruiting

  • Novartis Investigative Site

    Floridablanca, Colombia · Recruiting

  • Novartis Investigative Site

    San Gil, Colombia · Recruiting

  • Novartis Investigative Site

    Barranquilla, Atlántico, Colombia · Recruiting

  • Novartis Investigative Site

    Yopal, Casanare Department, Colombia · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.